Atai life sciences announces successful outcome of phase 2a biomarker trial of rl-007 in cognitive impairment associated with schizophrenia

Rl-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile
ATAI Ratings Summary
ATAI Quant Ranking